For the readers interested in the stock health of Teva Pharmaceutical Industries Limited (TEVA). It is currently valued at $9.22. When the transactions were called off in the previous session, Stock hit the highs of $9.49, after setting-off with the price of $9.26. Company’s stock value dipped to $9.20 during the trading on the day. When the trading was stopped its value was $9.29.Recently in News on September 8, 2021, Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant. Study examined efficacy of AJOVY, atogepant and rimegepant in the prevention of episodic migraine. You can read further details here
Teva Pharmaceutical Industries Limited had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $13.30 on 02/09/21, with the lowest value was $8.24 for the same time period, recorded on 07/19/21.
Teva Pharmaceutical Industries Limited (TEVA) full year performance was 5.69%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Teva Pharmaceutical Industries Limited shares are logging -30.68% during the 52-week period from high price, and 11.89% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $8.24 and $13.30.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1242821 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Teva Pharmaceutical Industries Limited (TEVA) recorded performance in the market was -3.73%, having the revenues showcasing -15.93% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 10.46B, as it employees total of 39717 workers.
Analysts verdict on Teva Pharmaceutical Industries Limited (TEVA)
During the last month, 1 analysts gave the Teva Pharmaceutical Industries Limited a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 15 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 9.94, with a change in the price was noted -0.98. In a similar fashion, Teva Pharmaceutical Industries Limited posted a movement of -9.66% for the period of last 100 days, recording 8,370,380 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TEVA is recording 2.43 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.09.
Teva Pharmaceutical Industries Limited (TEVA): Technical Analysis
Raw Stochastic average of Teva Pharmaceutical Industries Limited in the period of last 50 days is set at 46.54%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 35.33%. In the last 20 days, the company’s Stochastic %K was 31.85% and its Stochastic %D was recorded 28.80%.
Let’s take a glance in the erstwhile performances of Teva Pharmaceutical Industries Limited, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -3.73%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -16.68%, alongside a boost of 5.69% for the period of the last 12 months. The shares increased approximately by -2.00% in the 7-day charts and went up by -7.01% in the period of the last 30 days. Common stock shares were lifted by -15.93% during last recorded quarter.